Ovarian stimulation of IVF patients: effects of the reversible hypogonadotrophic state induced by GnRH agonist

• Published in: Human reproduction (Oxford) 1988-10, Vol.3 (suppl-2), p.39-41
• Main Authors: Crosignani, P.G., Ragni, G., Lombroso, G.C., Scarduelli, C., De Lauretis, L., Caccamo, A., Dalprà, L., Cavioni, V., Cristiani, C., Wyssling, H., Olivares, M.D., Perotti, L.
• Format: Article
• Language: English
• Subjects: Adult; Buserelin - therapeutic use; clomiphene; Clomiphene - therapeutic use; Drug Therapy, Combination; Female; Fertilization in Vitro; GnRH agonist; HMG; Humans; Menotropins - therapeutic use; Menstrual Cycle - drug effects; Norethindrone - therapeutic use; ovarian stimulation; Ovulation Induction
• ISSN: 0268-1161; 1460-2350
• DOI: 10.1093/humrep/3.suppl_2.39

Multiple ovulation was induced in 122 hypogonadotrophic IVF patients with large doses of HMG. The hypogonadotrophic state, short and reversible, was obtained by nasal administration of a GnRH agonist (200 μg, five times per day). In the 97 induced cycles, a mean of 9.1 follicles was recorded. A comparison of the results obtained for 36 patients who had already been treated with clomiphene and HMG showed both significantly more follicles per cycle (8.5 versus 3.0) and an increase in oocytes retrieved (6.7 versus 1.3) when treated with the agonist and HMG. In addition 11 of 18 already poorly responsive patients had normal responses. The luteal phase was supported by either HCG or progesterone injection. Plasma progesterone profiles were satisfactory and, as expected, the highest progesterone concentrations were associated with HCG treatment.